Drug-induced Hypotension Clinical Trial
Official title:
Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects
Hypotension does not occur with Maraviroc at a dose of 600 mg/day
Status | Completed |
Enrollment | 51 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Epzicom Maraviroc once daily dosing Exclusion Criteria: - Maraviroc with any other back bone |
Observational Model: Case-Only, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Nicholaos C Bellos, MD | GlaxoSmithKline |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hypotension related to once daily Maraviroc dosing | Blood pressure lowering secondary to Maraviroc 600 mg once daily dosing | 48 Weeks | Yes |